1. Home
  2. TALK vs TBPH Comparison

TALK vs TBPH Comparison

Compare TALK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TALK
  • TBPH
  • Stock Information
  • Founded
  • TALK 2012
  • TBPH 2013
  • Country
  • TALK United States
  • TBPH United States
  • Employees
  • TALK N/A
  • TBPH N/A
  • Industry
  • TALK Medical/Nursing Services
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • TALK Health Care
  • TBPH Health Care
  • Exchange
  • TALK Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • TALK 534.6M
  • TBPH 485.8M
  • IPO Year
  • TALK N/A
  • TBPH N/A
  • Fundamental
  • Price
  • TALK $3.36
  • TBPH $9.52
  • Analyst Decision
  • TALK Buy
  • TBPH Buy
  • Analyst Count
  • TALK 5
  • TBPH 4
  • Target Price
  • TALK $4.38
  • TBPH $13.75
  • AVG Volume (30 Days)
  • TALK 1.1M
  • TBPH 203.5K
  • Earning Date
  • TALK 02-20-2025
  • TBPH 02-24-2025
  • Dividend Yield
  • TALK N/A
  • TBPH N/A
  • EPS Growth
  • TALK N/A
  • TBPH N/A
  • EPS
  • TALK N/A
  • TBPH N/A
  • Revenue
  • TALK $181,291,000.00
  • TBPH $63,192,000.00
  • Revenue This Year
  • TALK $28.22
  • TBPH $11.41
  • Revenue Next Year
  • TALK $23.48
  • TBPH $37.36
  • P/E Ratio
  • TALK N/A
  • TBPH N/A
  • Revenue Growth
  • TALK 31.50
  • TBPH 15.93
  • 52 Week Low
  • TALK $1.60
  • TBPH $7.44
  • 52 Week High
  • TALK $3.92
  • TBPH $10.90
  • Technical
  • Relative Strength Index (RSI)
  • TALK 53.87
  • TBPH 51.10
  • Support Level
  • TALK $2.92
  • TBPH $9.46
  • Resistance Level
  • TALK $3.24
  • TBPH $10.90
  • Average True Range (ATR)
  • TALK 0.13
  • TBPH 0.44
  • MACD
  • TALK 0.01
  • TBPH 0.05
  • Stochastic Oscillator
  • TALK 74.36
  • TBPH 43.92

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue primarily stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: